Clinical trials: Behaviour
Adjunctive Treatment of Major Depressive Disorder
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
The clinical trial is a Phase 2, double-blind, randomized, placebo controlled study in Major Depressive Disorder (MDD) participants currently treated with antidepressant therapy.
- Trial name
- NCT04103892
- Testing
- CLE-100
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 146 people
- Sponsor
- Clexio Biosciences Ltd.
Major Depressive Disorder (MDD)
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
- Trial name
- NCT00448292
- Testing
- PRX-00023
- Where
- 21 sites in United States
- Volunteers
- 330 people
- Sponsor
- Epix Pharmaceuticals, Inc.
Lung Cancer, Non-small Cell Lung Cancer
An Evaluation of the Clinical Treatment and Patient Values and Preferences of Patients Suffering From Advanced Non-small Cell Lung Cancer (NSCLC) Undergoing Chemotherapy
The main purpose of this study is the identification, description, and segmentation of non-small cell lung cancer (NSCLC) patients based on their value appraisal of treatment outcomes and all intermediate states of health, to…
- Trial name
- NCT00721981
- Where
- 8 sites in Germany
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Depressive Disorder, Depression
Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)
To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who…
- Conditions
- Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders
- Trial name
- Pyxis (NCT01360645)
- Testing
- OPC-34712 + ADT
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 826 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Smoking, Smoking Behaviors
CSD210903: A Study to Determine Subject Puffing Patterns of a Heated Tobacco Product With Four Non-Combusted Cigarette Variants in an Ambulatory Setting
This is a multi-center, open-label, parallel-cohort-study to evaluate the puffing patterns of healthy adult consumers of tobacco products switching from a usual brand (UB) combustible cigarette (CC) and/or a UB Heated Tobacco…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT05307822
- Testing
- Non-combusted cigarette variant 42001401, Non-combusted cigarette variant 42001399, Non-combusted cigarette variant 40007386
- Where
- 7 sites in United States
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Pain
Delayed Release Diclofenac Sodium Formulation vs Voltaren®
This is a single-centre, open-label, randomised, three-arm crossover study with a fourth fixed arm in a subset of subjects. Up to 36 healthy male volunteers will participate in the study.
- Trial name
- NCT02714842
- Testing
- Radiolabelled Diclofenac Tablet A, Radiolabelled Diclofenac tablet B, Radiolabelled Diclofenac tablet C
- Where
- United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- BDD Pharma Ltd
Fluid Intake in Athletes, Sweating Rate in Athletes
Validity of Smart Cap and Smart Sweat Patch
The main objectives are to determine the validity of a Smart Cap in measuring fluid intake during running and fitness exercise and the validity of a Smart Sweat Patch in measuring sweat rate and sweat chloride concentration…
- Conditions
- Fluid Intake in Athletes, Sweating Rate in Athletes, Sweat Chloride Concentration in Athletes
- Trial name
- NCT04920266
- Testing
- Smart Cap, running and fitness exercisers only, Sweat Patch, all subjects- running, fitness, cycling, Reference sweat patch, all subjects - running, fitness, cycling
- Where
- 3 sites in United States
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Faecal Incontinence, Chronic Constipation
Outcome Research in Bowel Irrigation Techniques for the Treatment of Chronic Constipation and/or Faecal Incontinence
This clinical investigation is a post-market, exploratory, randomised, parallel, open-label investigation comparing two UKCA/CE-marked transanal irrigation products for the management of faecal incontinence and/or chronic…
- Trial name
- ORBIT-1 (NCT07473622)
- Testing
- Transanal irrigation
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Qufora A/S
Binge-Eating Disorder
Technology Assisted Treatment for Binge Eating Behavior
Binge-eating behavior is a central feature of eating disorders (e.g., binge-eating disorder, bulimia nervosa, anorexia nervosa-binge-eating/purging subtype) and is associated with higher rates of psychopathology, psychosocial…
- Trial name
- NCT05829941
- Testing
- Smartwatch app to deliver binge-eating CBT strategies, Reminder control condition
- Volunteers
- 30 people
- Sponsor
- HabitAware Inc.
Pancreas Cancer, Hepatobiliary Cancer
NCI SBIR Contract for Patient Navigation Tool Prototype Development
GMG ArcData will create a mobile-based application to improve communications and data exchange among patients and navigators involved in new pancreas surgery oncology episodes of care.
- Conditions
- Pancreas Cancer, Hepatobiliary Cancer, Patient Engagement
- Trial name
- NCT04892927
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GMG Arcdata LLC
Alzheimer's Disease
Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease
Alzheimer's disease is a medical illness that damages the brain and causes problems with memory, mood and behavior. A substance called acetylcholine (ACh), which is naturally produced in the body, plays an important role in the…
- Trial name
- NCT00104442
- Testing
- Rivastigmine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Novartis
Attention Deficit Hyperactivity Disorder (ADHD)
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to gain initial safety, tolerability, pharmacokinetic, and efficacy information on SPD489 in preschool children 4-5 years old who are diagnosed with ADHD.
- Trial name
- NCT02402166
- Testing
- SPD489
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- Shire
Smoking, Tobacco
CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers
The purpose of this Actual Use Study (AUS) is to investigate how United States (US) adult tobacco consumers 21 to 60 years of age, inclusive, who are regular smokers (≥5 cigarettes/day on at least 20 of the past 30 days) will use…
- Trial name
- NCT05960305
- Testing
- P1213416, P1213422, P1213716
- Where
- 12 sites in United States
- Volunteers
- 1,845 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation
A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin
To evaluate the absorption, safety, and tolerability of a varenicline solution and a varenicline patch applied to the skin.
- Trial name
- NCT00774605
- Testing
- Varenicline free base solution, Varenicline free base patch
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Disorder, Major, Recurrence
Study Evaluating Venlafaxine ER in Recurrent Depression
The purpose of this study is to review the long-term comparative efficacy of venlafaxine ER in achieving and sustaining remission (wellness) in patients with recurrent major depression
- Trial name
- NCT00046020
- Testing
- Venlafaxine ER
- Volunteers
- 1,096 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
NO VAPE + 12 Weeks of Standard CBT, Sham NO VAPE + 12 Weeks Standard CBT
Trial of Novel, On-Demand Virtual Reality to Amplify Practice Efficacy (NO VAPE) Added to Cognitive Behavioral Therapy for Nicotine Vaping Cessation
3. General Description of Study Design The proposed study will evaluate the effect of adding a VR app with CBT-embedded content to a 12-session individual CBT treatment program.
- Trial name
- NO VAPE (NCT07223879)
- Testing
- NO VAPE VR app with CBT-embedded content with a 12-session individual CBT treatment program
- Volunteers
- 90 people
- Sponsor
- Charles River Analytics
Quality of Life
Medical Affairs Pharmaceutical Physician Work-related Quality of Life (MAPPWrQoL) Instrument Development and Patient Registry (MAPPWrQoLReg)
Existing evidence has shown that medical affairs pharmaceutical physicians (MAPPs), are a core function within the pharmaceutical industry.
- Trial name
- NCT05123846
- Where
- United Kingdom
- Volunteers
- 180 people
- Sponsor
- Medialis Ltd.
Alzheimer Disease
Virtual Patient Behavioral Response Training for Family Caregivers
Our study is designed to help caregivers of someone with Alzheimer's Disease and related dementia to understand and deal with the difficult behaviors of a person with dementia.
- Trial name
- NCT04489303
- Testing
- Caring Response App, Traditional Educational/Resources Program
- Where
- United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Photozig, Inc.
Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less)
Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB
This study evaluates the use of a NICU clinical integration system (Dashboard and accessories) in improving the quality of care delivered, patient health outcomes, and parent and clinician satisfaction.
- Conditions
- Preterm Birth, Low; Birthweight, Extremely (999 Grams or Less), Neonatal Infection, Satisfaction
- Trial name
- NCT03673579
- Testing
- NICU Dashboard
- Where
- United States
- Sponsor
- Philips Healthcare
Major Depressive Disorder
An Open-Label Study of Azetukalner in Major Depressive Disorder
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of…
- Trial name
- X-NOVA-OLE (NCT06922110)
- Testing
- Azetukalner
- Where
- 71 sites in United States, Finland and 1 more
- Volunteers
- 460 people
- Sponsor
- Xenon Pharmaceuticals Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.